HDFC Mutual Fund reduced its shareholding in piramal pharma by 2.005% to 7.015% of the paid-up equity share capital as of July 14, 2026. The divestment involved the sale of 26,688,471 equity shares through the open market. This change follows a previous disclosure where the fund held a 9.034% stake as of June 26, 2025.

The transaction was disclosed to the stock exchanges in accordance with Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The letter was submitted by Dinesh Bhakade, Lead - Compliance Governance at HDFC Asset Management Company Limited, the investment manager for the schemes of HDFC Mutual Fund.

Shareholding Details

The reduction in stake was executed across several schemes managed by HDFC Mutual Fund, including the HDFC BSE 500 ETF, HDFC Focused Fund, and HDFC Flexi Cap Fund. The acquirer clarified that it does not belong to the promoter or promoter group of the target company.

The following table outlines the changes in the shareholding pattern:

Capital Structure

The paid-up equity share capital of Piramal Pharma Limited was reported at ₹13,31,34,81,300, comprising 1,33,13,48,130 equity shares of ₹10 each. This capital base remained unchanged before and after the transaction. The shares of the company are listed on BSE Limited and the National Stock Exchange of India Limited.

Piramal Pharma has successfully completed a US Food and Drug Administration (FDA) inspection at its Sellersville manufacturing facility. Following the conclusion of the inspection, the US FDA has formally issued the inspection report, marking a key regulatory development for the company.

US FDA Inspection at Sellersville Facility

The successful completion of the US FDA inspection at the Sellersville manufacturing facility underscores Piramal Pharma's compliance with regulatory standards set by one of the world's most stringent pharmaceutical oversight bodies. The issuance of the inspection report by the US FDA follows the conclusion of the on-site review at the facility.

The Sellersville facility is part of Piramal Pharma's manufacturing network, and the successful regulatory inspection reflects the company's adherence to quality and compliance requirements expected by the US FDA. The formal issuance of the inspection report is a standard procedural step following the completion of such regulatory reviews.